Orchestra BioMed Holdings (OBIO) Non Operating Investment Income (2022 - 2026)
Orchestra BioMed Holdings' (OBIO) quarterly Non Operating Investment Income came in at -$100000.0 in Q1 2026, down 566.67% year-on-year from $21428.6 in Q1 2025, and down 766.67% on a QoQ basis from $15000.0 in Q4 2025.
Orchestra BioMed Holdings (OBIO) Non Operating Investment Income (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has 5 years of Non Operating Investment Income data on file, last reported at -$100000.0 in Q1 2026.
- On a quarterly basis, Non Operating Investment Income fell 566.67% year-over-year to -$100000.0 in Q1 2026; TTM through Mar 2026 was -$77000.0, a 134.84% decrease from a year earlier, with the FY2025 full-year figure at $8000.0, down 87.1% from the prior year.
- Non Operating Investment Income for Q1 2026 stood at -$100000.0, down from $15000.0 in the prior quarter.
- Over the last five years, Non Operating Investment Income for OBIO reached as high as $1.7 million in Q2 2022 and fell as low as -$1.2 million in Q4 2022.
- Historically, Non Operating Investment Income has averaged $7058.8 across 5 years, with a median of -$15000.0 in 2024.
- Across the five-year window, Non Operating Investment Income jumped 536.84% in 2024 and plunged 850.0% in 2025, its largest moves.
- Year by year, Non Operating Investment Income stood at -$1.2 million in 2022, then surged by 104.24% to $51000.0 in 2023, then jumped by 154.9% to $130000.0 in 2024, then sank by 88.46% to $15000.0 in 2025, then slumped by 766.67% to -$100000.0 in 2026.
- Per Business Quant data, the three most recent Non Operating Investment Income figures were -$100000.0 in Q1 2026, $15000.0 in Q4 2025, and $29000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Orchestra BioMed Holdings | 235.83 Mn | 141.43 Mn | 78,000.00 | -100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -100,000.00 |
| Mar 31, 2026 | -100,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | -21,000.00 |
| Jun 30, 2025 | -21,000.00 |
| Mar 31, 2025 | -15,000.00 |
| Mar 31, 2025 | -15,000.00 |
| Dec 31, 2024 | 130,000.00 |
| Dec 31, 2024 | 130,000.00 |
| Sep 30, 2024 | 121,000.00 |
| Sep 30, 2024 | 121,000.00 |
| Jun 30, 2024 | -15,000.00 |
| Jun 30, 2024 | -15,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | 51,000.00 |
| Dec 31, 2023 | 51,000.00 |